Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

被引：2

作者：

Rauch, Simon ^{[1
]}

Fong, Dominic ^{[2
,3
]}

Morra, Elisa ^{[4
]}

Maines, Francesca ^{[5
]}

Caffo, Orazio ^{[5
]}

Spizzo, Gilbert ^{[2
]}

机构：

[1] F Tappeiner Hosp, Dept Internal Med, Via Rossini 5, Merano 39012, Italy

[2] Dept Haematol & Oncol, Dept Internal Med, Merano, Italy

[3] Med Univ Innsbruck, Dept Internal Med V Hematol & Oncol, Innsbruck, Austria

[4] F Tappeiner Hosp, Dept Cariol, Merano, Italy

[5] Santa Chiara Hosp, Dept Oncol, Trento, Italy

来源：

PROSTATE INTERNATIONAL | 2016年 / 4卷 / 02期

关键词：

Abiraterone acetate; Atrial fibrillation; Prostate cancer;

D O I：

10.1016/j.prnil.2016.02.002

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit its use in patients with atrial fibrillation. Methods: We retrospectively reviewed the clinical records of 85 metastatic castration-resistant prostate cancer patients treated with AA at our institutions and identified six patients suffering from concomitant atrial fibrillation. Results: In these six patients, the median duration of AA treatment was 11.5 months (range 4-22 months) with a biochemical response in three patients. No significant cardiac events were observed during the treatment. Conclusion: Our data suggest that AA may be safely administered in patients with atrial fibrillation. Copyright (C) 2016 Asian Pacific Prostate Society, Published by Elsevier.

引用

页码：54 / 55

页数：2

共 12 条

[1] Electrical, contractile and structural remodeling during atrial fibrillation [J].

Allessie, M ;

Ausma, J ;

Schotten, U .

CARDIOVASCULAR RESEARCH, 2002, 54 (02) :230-246

[2] LEFT ATRIAL SIZE AND THE RISK OF STROKE AND DEATH - THE FRAMINGHAM HEART-STUDY [J].

BENJAMIN, EJ ;

DAGOSTINO, RB ;

BELANGER, AJ ;

WOLF, PA ;

LEVY, D .

CIRCULATION, 1995, 92 (04) :835-841

[3] Left atrial size and risk for all-cause mortality and ischemic stroke [J].

Bouzas-Mosquera, Alberto ;

Broullon, Francisco J. ;

Alvarez-Garcia, Nemesio ;

Mendez, Elizabet ;

Peteiro, Jesus ;

Gandara-Sambade, Teresa ;

Prada, Oscar ;

Mosquera, Victor X. ;

Castro-Beiras, Alfonso .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (10) :E657-E664

[4] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[5] Treatment of prostate cancer in unfit senior adult patients [J].

Falci, Cristina ;

Morello, Elisabetta ;

Droz, Jean Pierre .

CANCER TREATMENT REVIEWS, 2009, 35 (06) :522-527

[6] Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study [J].

Heeringa, J ;

van der Kuip, DAM ;

Hofman, A ;

Kors, JA ;

van Herpen, G ;

Stricker, BHC ;

Stijnen, T ;

Lip, GYH ;

Witteman, JCM .

EUROPEAN HEART JOURNAL, 2006, 27 (08) :949-953

[7] Left atrium size and the risk of cardiovascular death in middle-aged men [J].

Laukkanen, JA ;

Kurl, S ;

Eränen, J ;

Huttunen, M ;

Salonen, JT .

ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (15) :1788-1793

[8] Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer [J].

O'Donnell, A ;

Judson, I ;

Dowsett, M ;

Raynaud, F ;

Dearnaley, D ;

Mason, M ;

Harland, S ;

Robbins, A ;

Halbert, G ;

Nutley, B ;

Jarman, M .

BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2317-2325

[9] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors [J].

Procopio, Giuseppe ;

Grassi, Paolo ;

Testa, Isabella ;

Verzoni, Elena ;

Torri, Valter ;

Salvioni, Roberto ;

Valdagni, Riccardo ;

de Braud, Filippo .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05) :479-482

[10] Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy [J].

Ryan, Charles J. ;

Smith, Matthew R. ;

de Bono, Johann S. ;

Molina, Arturo ;

Logothetis, Christopher J. ;

de Souza, Paul ;

Fizazi, Karim ;

Mainwaring, Paul ;

Piulats, Josep M. ;

Ng, Siobhan ;

Carles, Joan ;

Mulders, Peter F. A. ;

Basch, Ethan ;

Small, Eric J. ;

Saad, Fred ;

Schrijvers, Dirk ;

Van Poppel, Hendrik ;

Mukherjee, Som D. ;

Suttmann, Henrik ;

Gerritsen, Winald R. ;

Flaig, Thomas W. ;

George, Daniel J. ;

Yu, Evan Y. ;

Efstathiou, Eleni ;

Pantuck, Allan ;

Winquist, Eric ;

Higano, Celestia S. ;

Taplin, Mary-Ellen ;

Park, Youn ;

Kheoh, Thian ;

Griffin, Thomas ;

Scher, Howard I. ;

Rathkopf, Dana E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (02) :138-148

← 1 2 →